Commodore Capital LP

Registered adviser

CIK

1831942

Location

NEW YORK, NY

Portfolio Value

Mid $1,678,990,921

Diversification

Diversified

Filing Date

Global Rank

#1,800 / 8,819 ▼ 206

Top Industry

Biotechnology 82.7%

Period ended 4 months ago

Filed Aug 14, 2026 · 3mo

23 quarters · since Dec 2020

Regulatory profile

From Form ADV, the SEC filer profile, 13D/13G type codes and N-CEN, never from the name.

Holder type

Registered adviser

Form ADV roster, Oct 1, 2026

Form ADV adviser

CRD 304370

Roster of Oct 1, 2026

Regulatory AUM

$2,369,313,969

Main clients

Pooled investment vehicles (100% of AUM)

Private funds

1 fund · Hedge funds

Focus by fund count, roster of Oct 1, 2026

$2,369,313,969 gross assets

LEI

549300729275T4UVFT94

Private funds on Schedule D 7.B.(1)

As filed Mar 22, 2024; SEC's bulk Form ADV archive ends with 2024 filings.

$1,356,387,341 gross assets in 1 fund Hedge funds $1,356,387,341 (1)

Form ADV history

Monthly rosters from Dec 2019; each row is a run with the same figures, newest first.

Rosters	Regulatory AUM	Main clients
Apr 2026 to Oct 2026	$2,369,313,969	Pooled investment vehicles (100%)
Apr 2025 to Mar 2026	$1,763,757,281	Pooled investment vehicles (100%)
Apr 2024 to Mar 2025	$1,356,387,341	Pooled investment vehicles (100%)
May 2023 to Mar 2024	$814,632,508	Pooled investment vehicles (100%)
Apr 2023	$814,632,508	Pooled investment vehicles (100%)
Apr 2022 to Mar 2023	$538,687,313	Pooled investment vehicles (100%)

4 earlier changes not shown.

Stated strategy

Private markets Form ADV Part 2A, Mar 31, 2026 · original

In the firm's words

Private markets: focusing on early-stage public and late-stage private companies.

Portfolio style

Measured from the filed 13F common-share book for Jun 30, 2026, never from the firm's own description.

Style

Concentrated

The top 10 positions are 68.2% of the book (60%+)

Turnover

Medium turnover

52.9% over the last four quarters (30% to under 100%)

Horizon

Medium horizon

Value-weighted holding period 7.2 quarters (4 to under 12)

Closest benchmark: the Russell 2000 as of 2026-06-30, active share 98.0%; sector active share 90.3% against the combined 13F book's sector weights.

Over time 23 measured quarters

How the bands are measured

Style bands measure the filed 13F common-share book each closed quarter, tested in this order. Unknown: under $10,000,000 of valued equity or 5 stocks. Index-like (100+ stocks): active share of 20% or less against the closest benchmark, which is the S&P 500, S&P MidCap 400, S&P SmallCap 600, Russell 1000, Russell 2000, Nasdaq-100 or Dow Jones Industrial Average (weighted by an index-tracking fund's reported holdings or the index's constituents nearest the quarter end, over the names resolved to companies, and only when those are 90%+ of its weight) or every 13F filer's combined book, or index series holding 80%+ of the registered fund assets it advises (N-CEN) and equal to 50%+ of its book. Systematic-like: 500+ stocks, 100%+ annual turnover and a top 10 weight of 25% or less. Concentrated: a top 10 weight of 60%+ or 12 or fewer effective positions. Diversified active: none of these. Turnover is the smaller of buys and sells over average equity value, summed over four quarters: low under 30%, high 100%+. Horizon is the value-weighted number of quarters each position has been held: short under 4, long 12+.

Clone Performance

Build a hypothetical price-return history from this filer's public 13F holdings.

View clone backtest

Portfolio Concentration

33 tracked positions · as of Jun 30, 2026 · Δ vs Mar 31, 2026

Top Position

13.4%

+3.6 pts

Top 5

45.7%

+7.9 pts

Top 10

68.2%

+6.8 pts

HHI

622

Diversified+129

Portfolio Trend

23 quarters · across all stocks

Sector Breakdown

As of Jun 30, 2026

Sector	% Portfolio	Value	Positions
Healthcare	99.4%	$1,668,320,921	31
Financial Services	0.6%	$10,670,000	2

Last Quarter's Activity

Export CSV

Jun 30, 2026 vs Mar 31, 2026

Added To

Positions the filer increased

6 positions

Ticker	Company	Δ Shares	Shares	Value
EYPT	EyePoint, Inc.	+1,775,000	4,600,000	$65,780,000
RLMD	Relmada Therapeutics, Inc.	+791,099	1,425,000	$9,861,000
ANTX	AN2 Therapeutics, Inc.	+599,967	2,933,680	$14,199,011
AVTX	Avalo Therapeutics, Inc.	+535,319	1,018,319	$18,818,535
ASMB	Assembly Biosciences, Inc.	+415,000	1,415,000	$38,884,200
COGT	Cogent Biosciences, Inc.	+161,993	3,050,000	$118,035,000
No positions match the current search.

Trimmed

Positions the filer reduced

9 positions

Ticker	Company	Δ Shares	Shares	Value
RLAY	Relay Therapeutics, Inc.	−5,000,000	12,000,000	$224,520,000
SABS	SAB Biotherapeutics, Inc.	−1,531,500	2,870,000	$11,193,000
CLDX	Celldex Therapeutics, Inc.	−1,346,616	1,350,000	$50,233,500
ALKS	Alkermes plc.	−1,200,000	3,000,000	$157,200,000
SYRE	Spyre Therapeutics, Inc.	−1,065,594	846,786	$75,177,661
—		−733,600	100,000	$12,350,000
TYRA	Tyra Biosciences, Inc.	−600,000	1,875,000	$59,887,500
KYMR	Kymera Therapeutics, Inc.	−500,000	250,000	$28,667,500
PHVS	Pharvaris N.V.	−493,970	1,425,000	$49,276,500
No positions match the current search.

New Positions

Positions the filer opened this quarter

5 positions

Ticker	Company	Shares	Value
TNGX	Tango Therapeutics, Inc.	2,250,000	$70,335,000
EDIT	Editas Medicine, Inc.	8,889,000	$28,800,360
IFRX	InflaRx N.V.	7,300,000	$16,352,000
RACC	Research Alliance Corp III	500,000	$5,350,000
VTGN	Vistagen Therapeutics, Inc.	2,788,620	$641,382
No positions match the current search.

Sold Out

Positions the filer fully exited

8 positions

Ticker	Company	Shares	Value
ERAS	Erasca, Inc.	3,175,000	$51,371,500
XENE	Xenon Pharmaceuticals Inc.	825,000	$47,973,750
NRIX	Nurix Therapeutics, Inc.	2,275,000	$35,262,500
CRVS	Corvus Pharmaceuticals, Inc.	2,258,735	$33,045,293
—		652,432	$21,843,423
OCUL	Ocular Therapeutix, Inc	2,575,000	$21,810,250
PALI	Palisade Bio, Inc.	7,181,062	$12,566,858
KPTI	Karyopharm Therapeutics Inc.	1,950,000	$10,861,500
No positions match the current search.

Portfolio Positions

Compact Export CSV View 13F filing

33 tracked positions · $1,678,990,921 total · filing declares 33 positions · $1,678,964,770 · as of Jun 30, 2026

All sectors Financial Services Healthcare

Ticker	Company	Type	Shares	Δ Shares	Value (USD)	% Δ Value	Held (qtrs)	Est. cost/share	% of Portfolio
RLAY	Relay Therapeutics, Inc. Healthcare	Reduced	12,000,000	-5,000,000	$224,520,000	+32.7%	5	$3.15	13.37%
ELVN	Enliven Therapeutics, Inc. Healthcare	Held	3,275,000	0	$166,206,250	+29.5%	14	$19.08	9.90%
ALKS	Alkermes plc. Healthcare	Reduced	3,000,000	-1,200,000	$157,200,000	+5.9%	9	$27.83	9.36%
COGT	Cogent Biosciences, Inc. Healthcare	Added	3,050,000	+161,993	$118,035,000	+6.2%	23	before history	7.03%
AMLX	Amylyx Pharmaceuticals, Inc. Healthcare	Held	5,650,000	0	$101,474,000	+29.2%	4	$10.57	6.04%
DFTX	Definium Therapeutics, Inc. Healthcare	Held	2,000,000	0	$94,080,000	+148.9%	2	$16.97	5.60%
SYRE	Spyre Therapeutics, Inc. Healthcare	Reduced	846,786	-1,065,594	$75,177,661	−22.1%	12	unpriced	4.48%
ANRO	Alto Neuroscience, Inc. Healthcare	Held	2,723,196	0	$71,865,142	+17.4%	3	$14.56	4.28%
TNGX	Tango Therapeutics, Inc. Healthcare	NEW	2,250,000	NEW	$70,335,000	NEW	1	$24.72	4.19%
EYPT	EyePoint, Inc. Healthcare	Added	4,600,000	+1,775,000	$65,780,000	+80.6%	2	$14.35	3.92%
TYRA	Tyra Biosciences, Inc. Healthcare	Reduced	1,875,000	-600,000	$59,887,500	−36.8%	6	$10.62	3.57%
DMRA	Damora Therapeutics, Inc. Healthcare	Held	1,939,000	0	$50,433,390	+0.4%	2	$25.70	3.00%
CLDX	Celldex Therapeutics, Inc. Healthcare	Reduced	1,350,000	-1,346,616	$50,233,500	−41.3%	6	$22.38	2.99%
PHVS	Pharvaris N.V. Healthcare	Reduced	1,425,000	-493,970	$49,276,500	−9.1%	11	$23.04	2.93%
LBRX	Lb Pharmaceuticals Inc Healthcare	Held	1,500,000	0	$48,682,500	+31.6%	4	unpriced	2.90%
ASMB	Assembly Biosciences, Inc. Healthcare	Added	1,415,000	+415,000	$38,884,200	+40.1%	4	$23.49	2.32%
EDIT	Editas Medicine, Inc. Healthcare	NEW	8,889,000	NEW	$28,800,360	NEW	1	$2.92	1.72%
KYMR	Kymera Therapeutics, Inc. Healthcare	Reduced	250,000	-500,000	$28,667,500	−54.1%	5	$34.43	1.71%
CATX	Perspective Therapeutics, Inc. Healthcare	Held	6,336,782	0	$21,608,426	−18.2%	2	$4.22	1.29%
IPSC	Century Therapeutics, Inc. Healthcare	Held	8,695,652	0	$21,304,347	+8.4%	2	$2.10	1.27%
ZURA	Zura Bio Ltd Healthcare	Held	3,250,000	0	$19,175,000	−0.8%	2	$6.04	1.14%
AVTX	Avalo Therapeutics, Inc. Healthcare	Added	1,018,319	+535,319	$18,818,535	+161.0%	9	$13.30	1.12%
IFRX	InflaRx N.V. Healthcare	NEW	7,300,000	NEW	$16,352,000	NEW	1	$1.88	0.97%
ANTX	AN2 Therapeutics, Inc. Healthcare	Added	2,933,680	+599,967	$14,199,011	+77.9%	2	$2.52	0.85%
		Reduced	100,000	-733,600	$12,350,000	−85.5%	15	unpriced	0.74%
SABS	SAB Biotherapeutics, Inc. Healthcare	Reduced	2,870,000	-1,531,500	$11,193,000	−33.6%	4	$2.26	0.67%
IKT	Inhibikase Therapeutics, Inc. Healthcare	Held	5,397,488	0	$10,956,900	+20.8%	7	$2.49	0.65%
RLMD	Relmada Therapeutics, Inc. Healthcare	Added	1,425,000	+791,099	$9,861,000	+123.5%	2	$5.98	0.59%
PEPG	PepGen Inc. Healthcare	Held	4,475,000	0	$8,055,000	+1.7%	4	$3.41	0.48%
RACC	Research Alliance Corp III Financial Services	NEW	500,000	NEW	$5,350,000	NEW	1	$10.42	0.32%
HLXC	Helix Acquisition Corp. III Financial Services	Held	500,000	0	$5,320,000	+4.7%	2	$10.24	0.32%
LONA	LeonaBio, Inc. Healthcare	Held	464,398	0	$4,267,817	−10.6%	3	$4.58	0.25%
VTGN	Vistagen Therapeutics, Inc. Healthcare	NEW	2,788,620	NEW	$641,382	NEW	1	$0.60	0.04%

Covers the securities this platform tracks: U.S.-listed common stock and the put/call positions reported on it. A 13F can also report security types outside that coverage — preferred shares, bonds, warrants, untracked share classes — so the filing's own declared total can exceed the figures above. The source filing is linked at the top of this table.